Cargando…
Characteristics of Patients Treated with JAK Inhibitors in Rheumatoid Arthritis before versus after VTE Risk Warnings
Background: Baricitinib (BARI) or Tofacitinib (TOFA) were the first Janus Kinase Inhibitors (JAKi) to be marketed in rheumatoid arthritis (RA). Concerns regarding venous thromboembolism (VTE) risk have emerged during the past years. The aim of the study was to compare the baseline characteristics of...
Autores principales: | Philippoteaux, Cécile, Deprez, Valentine, Nottez, Aurore, Cailliau, Emeline, Houvenagel, Eric, Deprez, Xavier, Philippe, Peggy, Pascart, Tristan, Flipo, René-Marc, Goëb, Vincent, Letarouilly, Jean-Guillaume |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9820905/ https://www.ncbi.nlm.nih.gov/pubmed/36615007 http://dx.doi.org/10.3390/jcm12010207 |
Ejemplares similares
-
Actual Persistence of Abatacept in Rheumatoid Arthritis: Results of the French-Ric Network
por: Salmon, Jean-Hugues, et al.
Publicado: (2020) -
Tocilizumab Effectiveness After Switching from Intravenous to Subcutaneous Route in Patients with Rheumatoid Arthritis: The RoSwitch Study
por: Darloy, Jean, et al.
Publicado: (2019) -
Comparison of Rheumatoid Arthritis Patients’ 2-Year Infliximab, Abatacept, and Tocilizumab Persistence Rates
por: Diep, Laetitia, et al.
Publicado: (2022) -
Treatment of Nongout Joint Deposition Diseases: An Update
por: Pascart, Tristan, et al.
Publicado: (2014) -
Body composition in patients with rheumatoid arthritis: a narrative literature review
por: Letarouilly, Jean-Guillaume, et al.
Publicado: (2021)